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Received 31Background & aims: Themotivations of patientswho consult a homeopathic (GP-Ho) or
conventional (GP-CM) general practitioner for supportive care during cancer treatment
have not beenwidely studied. We investigated the reasons why cancer patients consult a
GP-HoversusaGP-CM for supportive careand theGPs’motivations for their prescriptions.
Methods: This observational survey was carried out in France between October 2008
and October 2011. GPs across France were randomly selected and asked to recruit
four cancer patients each. At inclusion, the sociodemographic and clinical (including psy-
chological) characteristics and medical history of the patients were recorded by the GPs
and the patients noted their quality of life (QoL) and anxiety/depression using the
Quality of Life Questionnaire-C30 (QLQ-C30) and Hospital Anxiety and Depression Scale
(HADS) self-questionnaires. The main motivations of the patients regarding the type of
GP consultation and the main reasons for the GPs’ prescriptions were recorded.
Results: Six hundred and forty four patientswere included in the analysis: 399 consulted
a GP-CM (n = 112) and 245 a GP-Ho (n = 73). Patients consulting a GP-Howeremore often
female [OR = 1.93; 95%CI: 1.11e3.35; p = 0.02], employed in a professional capacity
[OR = 6.57; 95%CI: 1.96e21.99; p = 0.002], have a shorter time since cancer diagnosis
[OR = 2.19; 95%CI: 1.24e3.87; p = 0.007], have received targeted anticancer therapy
[OR = 3.70; 95%CI: 1.67e8.18; p = 0.001] and have a high QLQ-C30 score for constipation
[OR=1.01; 95%CI: 1.00e1.02; p = 0.001]. Patientsmainly consultedaGP-Ho to receiveover-
all care (73.5% vs. 64.9%; p = 0.024) andmedicines to prevent anticancer treatment-related
side-effects (63.7% vs. 41.4%; p < 0.0001). In contrast, patients consulted a GP-CM to
receive psychological care (50.1% vs. 40.8%; p = 0.021) and more information regarding
theoncologists’ strategic decisions (p< 0.0001). Therewas a significantly greater prescrip-
tion of psychotropic drugs by GP-CM (53.7% vs. 22.4%, p < 0.0001).ence: Karine Danno, Laboratoire BOIRON, 2 avenue de l’Ouest Lyonnais, 69510 Messimy, France.
e.danno@boiron.fr
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HomeopathyConclusions: Patients consulting a GP-Ho or GP-CM had different motivations for
seeking supportive care. There was a significantly greater prescription of psychotropic
drugs by GP-CM. Homeopathy (2016) 105, 289e298.
Keywords: Cancer; General practice; Cross-sectional survey; Supportive care;
Homeopathy; Complementary medicineIntroduction
Complementary and alternative medicines (CAMs) are a
diverse set of medical systems, practices or products that
fall outside the realm of conventional Western medicine
and are used alongside or instead of it. In practice few peo-
ple forego conventional medicine so the term integrative
medicine is increasingly preferred. CAM focuses on the
whole person and includes physical, emotional, mental
and spiritual health.1 Despite the fact that many CAM tech-
niques are controversial and are not validated by evidence-
based medicine, the use of CAM as integrative therapy by
cancer patients, in parallel with anticancer treatments pre-
scribed by oncologists, has increased considerably over the
past 30 years.2 Studies in France have shown that 30e60%
of cancer patients report consulting a CAM practitioner in
addition to their cancer specialist.3e5 Amore recent review
of the English literature published between 2000 and 2015
suggests that CAM use may be as high as 94.7% in some
groups of cancer patients.6
In France, the cancer plan of 2009e2013 aimed to guar-
antee each cancer patient a personalized, equivalent and
effective care programme and to reinforce the coordination
of care between health professionals to allow a better qual-
ity of life (QoL) during and after the disease.7 Regular con-
sultations with an oncologist are scheduled in advance and
the oncologists’ reports are sent to the patient’s regular
(treating) general practitioner (GP). The patient is then
free to consult their GP for supplementary care if any prob-
lems arise between oncology consultations.
Although there is no evidence of cancer ‘cure’ with
CAM, CAM can play an important role in supportive and
palliative care in oncology.8 Homeopathy is practised as
complementary medicine to cancer treatments and helps
in patient support. Supportive therapy is defined as “all
care and supports necessary for ill people, at the same
time as specific treatments, along all severe illnesses”.9
Several publications have attempted to define the motiva-
tions of cancer patients using CAM as supportive therapy.
The majority of patients use CAM to increase the body’s
chance of fighting the cancer, to reduce their symptoms
and to improve their physical and emotional health and
wellbeing.2,4,10e14 However, in two reports, 13e20% of
patients considered CAM as a potential cure for their
cancer2,14 and 17% thought it could prevent recurrence,14
even though the CAM was given in addition to conven-
tional anticancer treatments.
In a large cross-sectional study of European cancer cen-
tres providing integrative oncology treatments, 40.4% of
patients using CAM used homeopathy.15 In cancer pa-
tients, homeopathic medicines have been reported to in-crease global health status, subjective wellbeing and
QoL,16,17 increase life-expectancy,18 decrease fatigue,17
reinforce the natural defences of the body3 and improve
tolerance to anticancer treatments.3 In an ethnographic
study carried out among practitioners and users of homeop-
athy19 it was suggested that homeopathy can provide some
support to patients, especially to combat the stress and un-
certainty that derives from cancer and conventional treat-
ments. Homeopathy can be seen as a supportive therapy
to help patients live a better life with their cancer.
We present the results of survey carried out in France to
describe the motivations of patients seeking either homeo-
pathic or conventional integrative care from their
GP during treatment for cancer and the reasons GPs give
for their prescriptions.Materialandmethods
Study design
This prospective, observational cross-sectional survey
was carried out in France between October 2008 and
October 2011 among GPs known to prescribe either ho-
meopathic or conventional medicines, within the frame-
work of their usual medical practice. A scientific
committee was set up to agree the study protocol and
monitor the study progress.
The study was approved by the French National Data
Protection Commission (CNIL), the Advisory Committee
on Information Processing in Material Research in the
Field of Health (CCTIRS) and the French National Council
of Physicians (CNOM). As this was an observational study
and did not involve any modifications to the anticancer
treatments given to the patients or to the assessment of
any possible new treatments for cancer, ethical approval
was not required according to French law.Recruitment of general practitioners
A list of approximately 1200 GPs was randomly gener-
ated from a list of all GPs in France. These GPs were con-
tacted by telephone by a clinical research associate (CRA)
and the study was explained to them with the aim finding
400 GPs who would agree to participate (200 GP-Ho and
200 GP-CM). The GPs were asked to recruit four patients
each over a 6-month period with the aim of recruiting 1600
patients overall. Because of patient recruitment below the
desired level an additional 110 GPs were contacted by tele-
phone in March 2011 and asked to take part; thus a total of
1310 GPs were contacted.
Of these 1310 GPs, 679 (51.8%) agreed to participate in
the study. The study was explained to these GPs again and
Supportive care for cancer patients
K Danno et al
291
they were given the relevant documents and shown how to
complete them by the CRA. Only 187/679 (27.5%) GPs
were active and included at least one patient (Figure 1).
The main reasons given for non-participation were a lack
of time, the GP did not participate in studies and a lack
of eligible patients.
The participating GPs were divided into two groups de-
pending on their specialty: registered homeopathic GPs
who prescribed mainly homeopathic medicines (GP-Ho)
and GPs who prescribed mainly conventional medicines
(GP-CM). In France, most GPs who prescribe homeopathic
medicines undergo additional training on homeopathic
medicines during their medical training or as part of their
continuing professional development during their ongoing
practice.
Participating GPs received financial remuneration for
the study but the patients did not.
Recruitment of patients
Patients were eligible for inclusion in the study if they
had a solid tumour or a haematological malignancy, irre-
spective of the stage of the tumour or the anticancer treat-
ment received (surgery, radiotherapy and/or
chemotherapy). Patients were excluded if they had another
evolving malignancy or were unable to understand French.
The patients were divided into two groups depending on
the specialty of their GP: GP-Ho or GP-CM. The end of
recruitment was fixed at 31 October 2011.
All patients were given an information letter about the
study and gave their informed consent before taking part.Patients' therapeutic ch
Figure 1 Flow chart of theData collection by the general practitioners
The following data regarding the GPs were recorded at
the start of the study: age; gender; geographic location;
type of practice (urban/rural); and activity (Sector I with
health insurance contract for minimum fees, Sector II
with additional fees, or not linked to the state health
scheme).
At inclusion the GPs recorded the following sociodemo-
graphic and clinical data for each patient using a standard
form: age; gender; body mass index (BMI, kg/m2); socio-
professional group (8 categories); level of education (5 cat-
egories); marital status (4 categories); physician’s role
(regular treating physician or not); health insurance
(covered by additional health insurance or not, universal
illness coverage [French ‘CMU’] or not); type of cancer;
time since cancer diagnosis (<1 month, 1e6 months, >6
months); previous and current treatments for cancer (sur-
gery, radiotherapy, chemotherapy, hormone therapy,
immunotherapy, targeted therapy, graft/allograft, associa-
tion of one or more treatments); number of previous cycles;
current prescriptions (conventional and homeopathic med-
icines, number of drugs prescribed, proportion of homeo-
pathic medicines, number of patients who received at
least one prescription of homeopathic medicine) and cur-
rent supportive care (yes/no) and type. The GPs noted the
three main motivations of the patient (in hierarchic order)
for the consultation out of seven possibilities from a closed
list: (i) overall supportive care; (ii) psychological care; (iii)
information on the cancer and its evolution; (iv) comple-
mentary information regarding the oncologists’ decisionsoice of physician
study population.
Homeopathy
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Homeopand treatment strategies; (v) preventive or curative man-
agement of the side-effects of anticancer treatments; (vi)
better chance of cancer cure; (vii) other. The GPs also
made a note of their reasons for the prescription from a
list of four possibilities (more than one reason was
possible): (i) to improve tolerance of anticancer treatments;
(ii) to treat anxiety/depression; (iii) to improve compliance
with anticancer treatments; and other.Data collection by the patients
The following data were recorded by all patients at in-
clusion using a self-questionnaire: current status regarding
work (sick leave, full-time, unemployed, retired, part-time,
other); QoL using the European Organization for Research
and Treatment of Cancer (EORTC) Quality of Life
Questionnaire-C30 (QLQ-C30) (version 3)20; and anxi-
ety/depression using the Hospital Anxiety and Depression
Scale (HADS).21 The QLQ-C30 was administered accord-
ing to the recommendations of the EORTC.20 The 30 items
were pooled into 3 domains: (i) activity; (ii) symptoms;
(iii) overall health-related QoL. For the evaluation of activ-
ity (scale of 0e100), a high score represented a high level
of activity, for symptoms a high score represented a high
level of symptoms and for QoL a high score represented
a good QoL. The HADS score was interpreted as described
by Zigmond & Snaith21: score#7 = no anxiety/depression,
8e10 = suspected anxiety/depression, $11 = confirmed
anxiety/depression.Statistical analysis
Quantitative variables are expressed as number,
mean standard deviation (SD), 95% confidence intervals
(CI), median, first and third quartile, range (minimum and
maximum) and number of missing data. Qualitative vari-
ables are expressed as frequency, percentage, 95%CI and
number of missing data.
Quantitative variables were analysed using the Student’s
t-test and qualitative variables were analysed using the Chi-
square test or Fischer’s exact test. The possible association
between sociodemographic and clinical factors and type ofTable 1 Characteristics of the active general practitioners (GPs) (N = 185
Characteristic Conventional GP (N = 112) H
Age
Mean  SD 53.6  7.3 5
Sex
M/F (%) 95.5/6.5 6
Rural location (%) 32.6 1
<10,000 inhabitants 16.3 1
10,000e50,000 21.7 2
50,000e100,000 2.2 1
>100,000 17.4 1
Paris + surrounds 9.8 6
Sector of activity (%)
Sector 1 92.4 6
Sector 2 7.6 2
Not connected 0 4
Usual treating GP, yes (%) 98.2 7
p value in bold text indicates statistical significance.
* Student’s test.
y Fisher’s exact test.
athymedical care sought (i.e. conventional vs. homeopathic)
was evaluated by logistic regression analysis.
For the logistic regression analysis, a model was created
for the probability of receiving homeopathic supportive
care. The following factors were analysed in univariate
and multivariate models: (i) sociodemographic data; (ii)
cancer history (type and duration); (iii) previous or current
treatments (surgery, radiotherapy, hormone therapy,
chemotherapy, targeted therapy, immune therapy, trans-
plant/allograft, other); (iv) 15 scores for the QLQ-C30
scale (activity, QoL, symptoms); (v) HADS scores. The
multivariate model was built by stepwise selection with
an entry threshold of 0.10 and a cancellation threshold of
0.05. The variables type of cancer and time since diagnosis
were included in the final multivariate model irrespective
of their level of significance.
All statistical analyses were performed using SAS,
version 9.2.Results
Study population e general practitioners
The composition of the study population is summarized
in the flowchart in Figure 1. The characteristics of the 187
active GPs are summarized in Table 1. There was no signif-
icant difference between the age of GP-CM and GP-Ho but
significantly more GP-Ho were female (43.5% vs. 6.5%,
p < 0.0001). GP-Ho were significantly less frequently the
regular treating physician than GP-CM (78.3% vs.
98.2%, respectively; p < 0.0001).
The distribution of the participating GPs was in accor-
dance with French national data, with some slight differ-
ences. Most GP-CM were in the Ile-de-France, Nord-Pas
de Calais, PACA (south region) and Rho^ne-Alpes regions,
while GP-Ho were more frequently located in the Midi-
Pyrenees and PACA regions (data not shown).Study population e patients
A total of 668 were recruited. Twenty-four patients were
excluded from the final analysis as they did not fulfil the)
omeopathic GP (N = 73) Total (N = 185) p
2.8  6.4 53.2  6.9 0.485*
4.5/34.5 81.8/18.2 <0.0001y
9.4 27.3 0.034y
6.1 16.2
2.6 22.1
6.1 7.8
9.4 18.2
.5 8.4
6.1 81.8 <0.0001y
9.0 16.2
.8 1.9
8.3 90.6 <0.0001y
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inclusion criteria, thus the final analysis consisted of 644
patients (112 GP-CM recruited 399 patients and 73 GP-
Ho recruited 245 patients) (Figure 1).
The sociodemographic and clinical characteristics of
these patients are summarized in Table 2. Mean age
was 62.5  12.4 years and 51.6% were female. Patients
consulting a GP-CM were significantly older than those
consulting a GP-Ho (63.7  12.4 vs. 60.6  12.1 years;
p = 0.003) whereas patients consulting a GP-Ho were
more likely to be female (61.5% vs. 45.5%, respectively;
p < 0.0001). More patients consulting a GP-Ho were
employed in a professional occupation (p < 0.001)
(Table 2).Table 2 Sociodemographic and clinical characteristics of the study popul
Characteristic Conventional (N
Age (years) 63.7  12.4
Gender, female 182 (45.5)
Body mass index (kg/m2) 25.1  4.4
Socio-professional category
Farmer 15 (3.8)
Craftsman, storekeeper, manager 11 (2.8)
Executive and intellectual profession 28 (7.0)
Intermediate profession 29 (7.3)
Employee 52 (13.1)
Workman* 22 (5.5)
Retired 208 (52.3)
Other 33 (8.3)
Highest diploma obtained
Below secondary school examination* 251 (63.1)
Secondary school examination 73 (18.3)
Above secondary school examination 74 (18.6)
Marital status
Single or alone* 39 (9.8)
Married or partnership 295 (73.9)
Widowed or divorced 63 (15.8)
Other 2 (0.5)
Additional health insurance coverage 382 (95.7)
Universal Health Insurance coverage (CMU) 13 (3.3)
Time from cancer diagnosis (%)
<1 month 45 (11.3)
1e6 months 165 (41.5)
>6 months* 188 (47.2)
Previous or current anticancer treatments (%)
Surgery 274 (68.7)
Radiotherapy 146 (36.6)
Chemotherapy 193 (48.4)
Hormone therapy 72 (18.0)
Targeted therapy 12 (3.0)
Immunotherapy 3 (0.8)
Other 12 (3.0)
Transplant/allograft 3 (0.8)
Number of cycles of chemotherapy already received
1 63 (15.8)
2 22 (5.5)
$3 73 (18.3)
Other type(s) of supportive care already receivedy 272 (68.2)
Vitamins/minerals/food supplements/tonics 104 (26.1)
Anxiolytics/antidepressants/hypnotics 171 (42.8)
Homeopathy 28 (7.0)
Psychotherapy 47 (11.8)
Physiotherapy 40 (10.0)
Acupuncture 15 (3.8)
Osteopathy 10 (2.5)
Other 4 (1.0)
Values shown are n (%), or mean  standard deviation. p value in bold tex
* Value used as reference for statistical calculation.
y Prescribed by the treating GP or not.
z Student’s t-test for quantitative variables or Fisher’s exact test for qualitatThe most frequent malignancy in the study population
was breast cancer (34.0%) (Figure 2). There was no signif-
icant difference in time from cancer diagnosis in the two
groups (p = 0.148) (Table 2).
Two-thirds of the patients (68.3%) had previously under-
gone surgery for their cancer and half (50.2%) had received
chemotherapy with nearly half of these having received
three cycles or more (Table 2). A third of the patients in
the GP-Ho group (36.3%) had already received homeo-
pathic treatments as supportive care. More patients in the
GP-CM group had previously been treated with anxio-
lytics, antidepressants and hypnotics as supportive care
(42.8% vs. 33.9%, p = 0.025).ation (N = 644)
= 399) Homeopathic (N = 245) Total (N = 644) pz
60.6  12.1 62.5  12.4 0.003
151 (61.5) 333 (51.6) <0.0001
24.5  4.1 24.8  4.3
8 (3.3) 23 (3.6) <0.001
24 (9.8) 35 (5.4)
24 (9.8) 52 (8.1)
33 (13.5) 62 (9.6)
24 (9.8) 76 (11.8)
7 (2.9) 29 (4.5)
103 (42.0) 311 (48.4)
22 (9.0) 55 (8.6)
138 (56.6) 389 (60.6) 0.136
45 (18.4) 118 (18.4)
61 (25.0) 135 (21.0)
23 (9.4) 62 (9.6) 0.997
182 (74.3) 477 (74.1)
40 (16.3) 103 (16.0)
0 (0.0) 2 (0.3)
237 (96.7) 619 (96.1) 0.527
6 (2.4) 19 (3.0) 0.557
38 (15.6) 83 (12.9) 0.148
107 (43.9) 272 (42.4)
99 (40.6) 287 (44.7)
166 (67.8) 440 (68.3) 0.808
103 (42.0) 249 (38.7) 0.168
130 (53.1) 323 (50.2) 0.248
49 (20.0) 121 (18.8) 0.538
22 (9.0) 34 (5.3) 0.002
2 (0.8) 5 (0.8) 0.927
11 (4.5) 23 (3.6) 0.328
2 (0.4) 4 (0.6) 0.596
35 (14.3) 98 (15.2) 0.217
23 (9.4) 45 (7.0)
52 (21.2) 125 (19.4)
177 (72.2) 449 (69.7) 0.275
73 (29.8) 177 (27.5) 0.303
83 (33.9) 254 (39.4) 0.025
89 (36.3) 117 (18.2) <0.0001
42 (17.1) 89 (13.8) 0.055
30 (12.2) 70 (10.9) 0.379
25 (10.2) 40 (6.2) 0.001
8 (3.3) 18 (2.8) 0.570
12 (4.9) 16 (2.5)
t indicates statistical significance.
ive variables.
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Figure 2 Types of cancer among the study population.
Supportive care for cancer patients
K Danno et al
294
HomeopThere was no significant difference between GP-Ho and
GP-CM patients in HADS scores or QLQ-C30 scores at in-
clusion (Table 4), except for diarrhoea and constipation
where scores were significantly higher for GP-Ho patients
(p = 0.021 and p < 0.001, respectively).
Treatments provided by the general practitioners
during the study
Significant differences were observed between the two
groups of patients regarding the treatments prescribed dur-
ing the study and were in accordance with the preference of
the GPs for conventional or homeopathic medicines (Table
3). Conventional medicines were prescribed preferentially
(74.2%) by GP-CM and homeopathic medicines (76.3%)
by GP-Ho.Table 3 Types of medicines prescribed to the two groups of patients duri
GP-C
At least 1 treatment 339 (8
Conventional 296 (7
Anxiolytics 120 (3
Antidepressants 47 (11
Hypnotics and sedatives 47 (11
Other analgesics and antipyretics 40 (10
Propulsives 33 (8.
Drugs for peptic ulcer and gastro-oesophageal reflux disease 26 (6.
Opioids 26 (6.
Homeopathic 42 (10
Ignatia amara 7 (1.8
Nux vomica 8 (2.0
Gelsemium sempervirens 10 (2.
Arsenicum album 4 (1.0
China regia 3 (0.8
Arnica montana 2 (0.5
Passiflora compose 4 (1.0
Thuya occidentalis
Lycopodium clavatum
Phosphorus
Phytotherapy (unspecified herbal) 30 (7.
Food complements/trace elements/vitamins 46 (11
Other vitamin products, combinations 18 (4.
Values shown are n (%). p value in bold text indicates statistical significanc
athyThe most frequent medicines prescribed by GP-CM
were psychotropic drugs (anxiolytics 30.1%, antidepres-
sants 11.8%, hypnotics and sedatives 11.8%) (53.7% vs.
22.4% in the GP-Ho group) whereas the most frequent
medicines prescribed by GP-Ho were Ignatia amara
(17.6%), Nux vomica (14.7%) and Gelsemium sempervi-
rens (12.7%). Ignatia amara and Gelsemium sempervirens
are usually prescribed to treat anxiety and Nux vomica for
digestive disturbances.
Motivations of the patients for consulting their general
practitioner
At inclusion, patients were asked to list their three main
reasons (out of a closed list of seven) for consulting their
GP. Over two-thirds of patients wanted overall supportiveng the study
M (N = 399) GP-Ho (N = 245) Total (N = 644) p
5.0) 237 (96.7) 576 (89.4)
4.2) 99 (40.4) 395 (61.3) <0.0001
0.1) 28 (11.4) 148 (23.0) <0.0001
.8) 21 (8.6) 68 (10.6) 0.235
.8) 6 (2.4) 53 (8.2) <0.0001
.0) 16 (6.5) 56 (8.7) 0.150
3) 13 (5.3) 46 (7.1) 0.160
5) 9 (3.7) 35 (5.4) 0.122
5) 9 (3.7) 35 (5.4) 0.122
.5) 187 (76.3) 229 (35.6) <0.0001
) 43 (17.6) 50 (7.8)
) 36 (14.7) 44 (6.8)
5) 31 (12.7) 41 (6.4)
) 24 (9.8) 28 (4.3)
) 18 (7.3) 21 (3.3)
) 17 (6.9) 19 (3.0)
) 16 (6.5) 20 (3.1)
15 (6.1) 15 (2.3)
13 (5.3) 13 (2.0)
13 (5.3) 13 (2.0)
5) 26 (10.6) 56 (8.7) 0.176
.5) 45 (18.4) 91 (14.1) 0.015
5) 30 (12.2) 48 (7.5) <0.001
e.
Table 4 Quality of life scores for the two groups of patients at inclusion
GP-CM (N = 399) GP-Ho (N = 245) Total (N = 644) p
Depression scores, according to Zigmond & Snaith21
Missing data 29 30 59
Minimal or no depression (score #7) 133 (35.9) 8 (37.2) 213 (36.4) 0.402
Suspected depression (score 8e10) 99 (26.8) 47 (21.9) 146 (25.0)
Recognized depression (score $11) 138 (37.3) 88 (40.9) 226 (38.6)
Total 370 215 585
Anxiety scores, according to Zigmond & Snaith21
Missing 29 30 59
Minimal or no anxiety (score #7) 140 (37.8) 81 (37.7) 221 (37.8) 0.434
Suspected anxiety (score 8e10) 107 (28.9) 53 (24.7) 160 (27.4)
Recognized anxiety (score $11) 123 (33.2) 81 (37.7) 204 (34.9)
Total 370 215 585
QLQ-C30
Activity
Physical activity 69.4  23.5 70.4  24.5 69.8  23.8 0.634
Limitation due to physical status 53.1  30.1 55.2  30.7 53.9  30.3 0.430
Cognitive activity 70.8  23.5 70.6  26.8 70.7  24.7 0.949
Emotional activity 56.5  25.4 56.6  25.6 56.6  25.4 0.978
Social activity 60.2  29.2 57.6  30.1 59.2  29.5 0.304
Symptoms
Fatigue 50.3  27.5 52.2  26.7 51.0  27.2 0.427
Pain 36.2  28.0 38.1  29.1 36.9  28.4 0.435
Nausea/vomiting 18.9  24.0 22.2  27.3 20.1  25.3 0.133
Appetite 36.8  31.6 34.9  33.5 36.1  32.3 0.497
Constipation 16.7  25.3 25.1  29.9 19.8  27.4 <0.001*
Diarrhoea 10.3  21.9 14.9  24.7 12.0  23.0 0.021*
Insomnia 46.1  30.6 43.5  30.9 45.1  30.7 0.318
Dyspnoea 33.3  31.2 28.2  31.4 31.5  31.4 0.058
Financial 14.5  25.2 20.0  28.0 16.5  26.3 0.015*
Overall quality of life 45.6  20.1 47.7  19.8 46.3  20.0 0.221
Values shown are n (%), or mean  standard deviation. p value in bold text indicates statistical significance.
* Statistically significant (p < 0.05).
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toms beyond those due to the cancer (Table 5). The propor-
tion of patients who wanted overall supportive care and
treatments to prevent or relieve anticancer treatment-
related side-effects were significantly higher in the GP-
Ho group (73.5% vs. 64.9%, p = 0.024; and 63.7% vs.
41.4%, p < 0.0001, respectively). On the other hand, pa-
tients consulting a GP-CM more often wanted psycholog-
ical care (50.1% vs. 40.8%, p = 0.021) and additional
information regarding the oncologist’s treatment decisions
(46.4% vs. 27.3%, p < 0.0001).Motivations for the general practitioners’ treatment
decisions
The GP-CM and GP-Ho were also asked why they had
prescribed the various treatments to their patients
(Table 6). The most common reasons were to improveTable 5 Motivations* for the consultation with the general practitioner (GP
Motivations* Con
Overall supportive care 259
Psychological care 200
Information on the disease and its evolution 169
Complementary information on the oncologists’ strategic decisions 185
Treatment of side-effects linked to the anticancer treatments 165
Greater chance of cancer cure 150
Other 9 (2
Values shown are n (%). p value in bold text indicates statistical significanc
* From a closed list of seven possible motivations.the tolerance of anticancer treatments (32.6% vs. 58.0%,
respectively; p < 0.001) and to prevent or treat anxiety
and/or depression (50.4% vs. 66.1%, respectively;
p < 0.001) (Table 6). There was a significantly greater pre-
scription of antipsychotic drugs by GP-CM (53.7% vs.
22.4%, p < 0.0001).Analysis of the factors associated with homeopathic
consultations
Multivariate analyses of the sociodemographic and clin-
ical characteristics of the patients consulting GP-Ho
showed a statistically significant influence of female sex
[OR = 1.93; 95%CI: 1.11e3.35; p = 0.02], being employed
in a professional capacity [OR = 6.57; 95%CI:
1.96e21.99; p = 0.002], shorter time since cancer diag-
nosis (<1 month vs. >6 months) [OR = 2.19; 95%CI:
1.24e3.87; p = 0.007], the presence of targeted anticancer) in the two groups of patients
ventional GP (N = 399) Homeopathic GP (N = 245) p
(64.9) 180 (73.5) 0.024
(50.1) 100 (40.8) 0.021
(42.4) 88 (35.9) 0.105
(46.4) 67 (27.3) <0.0001
(41.4) 156 (63.7) <0.0001
(37.6) 108 (44.1) 0.103
.3) 9 (3.7) 0.289
e.
Homeopathy
Table 6 Reasons given by the general practitioners (GPs) for the prescriptions
Reasons Conventional GP
(N = 399)
Homeopathic GP
(N = 245)
Total
(N = 644)
p
To improve tolerance to anticancer drugs 130 (32.6) 142 (58.0) 272 (42.2) <0.001
To treat or prevent anxiety/depression 201 (50.4) 162 (66.1) 363 (56.4) <0.001
To increase compliance of the patient to the anticancer treatment 78 (19.5) 54 (22.0) 132 (20.5) 0.447
Other 83 (20.8) 35 (14.3) 118 (18.3) 0.038
Values shown are n (%). p value in bold text indicates statistical significance.
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Homeoptherapy (previous or current) [OR = 3.70; 95%CI:
1.67e8.18; p = 0.001] and a high QLQ-C30 constipation
score [OR = 1.01; 95%CI: 1.00e1.02; p = 0.001]
(Figure 3). No factor was significantly associated with
consultation with a GP-CM.Discussion
This large, observational, cross-sectional study shows
that in two groups of patients with similar levels of anxi-
ety/depression and QoL at inclusion, the main reasons for
consulting a GP-Ho were to eliminate the side-effects of
anticancer treatments and to receive overall supportive
care where more patients consulting a GP-CM expected
to receive psychological care. Our findings regarding GP-
Ho agree with those of previous reports that the majority
of cancer patients use CAM to reduce the side-effects of
cancer and its treatment and to improve their physical
and emotional health and wellbeing.2,4,10e12 The main
homeopathic medicines prescribed in this study, Ignatia
amara (17.6%), Nux vomica (14.7%) and Gelsemium1.00
1.30
1.5
1
1.01
1.00
1.22
-1 0 1
Sexe Féminin N= 580 ,  IC 95 % = [ 1.11 ; 3.35 ]
CSP - ouvrier N= 29 , IC 95 % = [ 1.00 ; 1.00 ]
CSP - Agriculteur N= 23 , IC 95 % = [ 0.48 ; 7.04 ]
CSP - Artisan, com., chef d'entr. N= 35 , IC 95 % = [ 1.96 ; 21.99 ]
CSP - Cadre et prof. Superieures N= 52 , IC 95 % = [ 0.81 ; 7.30 ]
CSP - Prof. intermédiaires N= 62 , IC 95 % = [ 0.96 ; 8.22 ]
CSP - employés N= 23 , IC 95 % = [ 0.45 ; 3.71 ]
CSP Retraités  N= 311 , IC 95 % = [ 0.6 ; 3.94 ]
CSP - Sans activité prof. N= 55 , IC 95 % = [ 0.55 ; 5.23 ]
Ancienneté du diagnostic < 1 mois N= 83 , IC 95 % = [ 1 ; 1 ]
Ancienneté du diagnostic entre 1 et 6 mois N= 272 , IC 95 % = [ 1.24 ;
3.87 ]
Ancienneté du diagnostic > 6 mois N= 287 , IC 95 % = [ 0.81 ; 1.83 ]
Ttt - Thérapeutiques ciblées N= 34 , IC 95 % = [ 1.67 ; 8.18 ]
QLQC30 - Constipation N= 583 , IC 95 % = [ 1 ; 1.02 ]
Groupe Allopathe
p=
Gend r fe ale N= 580, 95% I = [ 1.11 ; 3.35 ]
SPC - W rkman  9, 95%CI = [ 1.00 ; 1.00 ]
SPC - Farmer N= 23, 95%CI = [ 0.48 ; 7.04 ]
SPC - Craf sman, storekeeper, manager N= 35, 95%CI = [ 1.96 ; 21.99 ]
SPC -Intermedia profession N= 62, 95%CI = [ 0.96 ; 8.22 ]
SPC - Executive and intellectual profession N= 52, CI = [ 0.81 ; .  ]
SPC - Employee N= 76, 95% I = [ 0.45 ; 3 71 ]
SPC - etired N= 311, 95%CI = [ 0.60 ; 3.94 ]
SPC - Other N= 55, 95%CI = [ 0. ; 5.23 ]
Time from cancer i osis > 6 month  287 95%CI = [ 1 ; 1]
Time from cancer osis < 1 month N= 83, 95%CI = [ 1.24 ; 3.87 ]
Targeted therapy N= 34, 95%CI = [ 1.67 ; 8.18 ]
QLQC30 – Constipation N= 583, 95%CI = [ 1.00 ; 1.02 ]
SPC = Socio-professional category
CONVENTIONAL
Time from cancer i osis 1 - 6 months N= 272, 95%CI = [ 0.81 ; .83 ]
Figure 3 Multivariate analysis of the factors favouring consultatio
athysempervirens (12.7%) are traditionally prescribed to treat
anxiety, sleep disorders, digestive disturbances and
fatigue, which are frequent symptoms in cancer patients.
Cancer is accompanied by psychological suffering which
never completely disappears despite good organization of
conventional management (series of examinations and
anticancer treatments). Homeopathy is an individualistic
treatment where medicines are proposed to suit
individual requirements which may link very closely
with the components of conventional treatment. In
essence, resort to homeopathic treatments is largely
induced by the real or supposed effects of conventional
treatments. GP-CM prescribed psychotropic drugs to
address the psychological suffering. However, in one study
by Kelly et al., the use of the antidepressant paroxetine dur-
ing tamoxifen treatment was associated with an increased
risk of death from breast cancer.22
Multivariate analysis confirmed previous findings that
patients who consult a GP-Ho are more likely to be female
[OR = 1.93; 95%CI: 1.11e3.35; p = 0.02] and to be em-
ployed in a professional capacity [OR = 6.57; 95%CI:1.93
1.84
6.57
2.43
2.81
4
.70
3.70
2.19
2 3 4 5 6 7
Groupe Homéopathe
p=0.020
p=0.015
p=0.001
0.001
p=0.027
HOMEOPATHIC
n with a conventional or homeopathic general practitioner.
Supportive care for cancer patients
K Danno et al
297
1.96e21.99; p = 0.002].3,23,25 Furthermore, patients who
consulted a GP-Ho were more likely to have received or
be receiving targeted anticancer therapy [OR = 3.70;
95%CI: 1.67e8.18; p = 0.001] and to have a high QLQ-
C30 score for constipation [OR = 1.01; 95%CI:
1.00e1.02; p = 0.001]. To our knowledge, these latter ob-
servations have not been reported previously. In contrast to
other studies,24,25 the patients in our study consulted a GP-
Ho earlier in their disease than GP-CM patients
[OR = 2.19; 95%CI: 1.24e3.87; p = 0.007]. Indeed, a
recent report suggests that “CAM decision-making begins
with the diagnosis of cancer and encompasses three
distinct phases (early, mid and late), each marked by
unique aims for CAM treatment and distinct patterns of
information-seeking and evaluation”.26
When the profile of the GPs was examined, there was a
significantly higher proportion of female GP-Ho than GP-
CM (34.5% vs. 6.5%; p < 0.0001). Moreover, the GP-Ho
was the usual treating physician in only 78.3% of cases
(vs. 98.2% for GP-CM). This suggests that cancer patients
may consult a homeopathic physician who is not their reg-
ular physician specifically to receive homeopathic treat-
ments or another type of treatment to that prescribed by
their usual doctor. To our knowledge this has not been re-
ported previously.
In a study in Europe, Molassiotis et al. asked patients
who were not using CAM to note the reasons they did
not do so.11 Nearly half (43.4%) stated that they were
happy with conventional treatments, one-third (34.7%)
said that they never thought of CAM and 15.1% said
that they did not believe in CAM. Although we addressed
the patients’ motivations for using homeopathy in this
study, we did not asked the patients who consulted a
GP-CM what their attitudes and beliefs towards homeop-
athy were.
In France, it is rarely possible to consult a homeopathy
specialist for supportive care in the hospital setting.
However, it is clear that an increasing number of cancer
patients are turning to these therapies as part of their
integrative care irrespective of the views and beliefs of
health professionals about CAM. A large study of
CAM use in cancer patients conducted in 14 European
countries in 2005 showed that herbs were the most com-
mon CAM therapy in Turkey, Israel, Serbia, Czech Re-
public, Denmark, Italy, Switzerland, Spain and Greece
whereas homeopathy was the most common CAM in
Belgium.11 More recently in France, the MAC-AERIO
survey of 850 adults with solid or haematological malig-
nancies found that 60% of patients used CAM and that
33% of these used homeopathic treatments.5 Thompson
and Reilly reported that 75% of cancer patients were
satisfied with the homeopathic treatment they had
received as supportive care and that this had significantly
helped them regarding their symptoms.27 Simon et al.
also reported a high level of patient satisfaction with
CAM with good subjective results on their general status,
fatigue and nausea-vomiting.3
Healthcare staff in hospitals need to be aware of the rea-
sons why patients turn to CAM rather than conventionaltreatments as supportive care. Patients and healthcare
workers should be educated about CAM therapies for
which evidence of effectiveness exists and these therapies
should be offered to patients as part of their ongoing cancer
treatment. Training of healthcare workers about CAM of-
fers an opportunity to integrate different approaches into
patient management.11,28 GP-Ho and oncologists rarely
meet and there is no collaboration between GP-Ho and on-
cologists around the patient. Homeopaths should also be
educated about the conventional management of cancer pa-
tients and specialist GP-Ho should be trained to follow can-
cer patients. The goal should be better communication
between the oncologist, the homeopath and the patient.
In our study, over half of the GP-Ho (58.0%) prescribed
therapies aimed at improving tolerance to anticancer treat-
ments. This is an important consideration as better toler-
ance of anticancer treatments may lead to better
compliance and an increased probability of survival. The
patients resorted to homeopathy to help them better support
their disease and its treatments as well as its psychological
consequences.
Our study has several limitations. First, the two groups
of patients were very different and this could have intro-
duced a bias into the study. However, the regression anal-
ysis took into account and confirmed some of these
differences. Our observational study aimed to describe
the reality in day-to-day practice without anymodifications
to this practice. Secondly, we cannot exclude the possibil-
ity that some of the patients could have also used treat-
ments and/or consultations other than those reported. Our
survey did not take into account medications that were
taken either as self-treatment without a medical prescrip-
tion or following a pharmacist’s advice. In France, homeo-
pathic treatments can be delivered directly by a pharmacist
without a medical prescription. Thirdly, our study popula-
tion included relatively few GPs although the GPs were
well distributed across France. Finally, a previous report
suggested that cancer patients using CAM had a healthier
lifestyle, positive beliefs towards CAM and a desire to
participate in their own care.29 Our study mainly investi-
gated the motivations for seeking supportive care in terms
of medical needs and only the question about cancer cure
addressed the patients’ attitudes and beliefs towards
CAM.29 Patients who consulted a GP-CM were not asked
why they had not consulted a GP-Ho.
This study shows that patients consulting a GP-Ho ex-
pected to receive overall supportive care and therapies to
prevent cancer treatment-related side-effects, whereas
patients consulting a GP-CM sought psychological
care. The most common reasons for the GPs prescrip-
tions were to prevent or treat anxiety and/or depression
and to improve tolerance to anticancer treatments. There
was a significantly greater prescription of psychotropic
drugs by GP-CM while the most frequently prescribed
homeopathic medicines were those used to treat anxiety,
digestive disorders and fatigue. Further research is
needed to explore the potential benefits of homeopathic
medicines as integrative care in cancer patients. It would
be interesting to investigate which symptoms are mostHomeopathy
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Homeopfrequently reported among the cancer patients who con-
sult a GP-Ho.
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